1d:I[2890,["266","static/chunks/870fdd6f-4fcc92c129a57d11.js","970","static/chunks/970-91a3a37cc668faba.js","857","static/chunks/857-3b2a1421afa266d2.js","965","static/chunks/app/podcasts/episode/%5BpodcastEpisodeGuid%5D/page-e939c6b91b4a25d4.js"],"default"] 1e:I[1318,["266","static/chunks/870fdd6f-4fcc92c129a57d11.js","970","static/chunks/970-91a3a37cc668faba.js","857","static/chunks/857-3b2a1421afa266d2.js","965","static/chunks/app/podcasts/episode/%5BpodcastEpisodeGuid%5D/page-e939c6b91b4a25d4.js"],"default"] 1f:T6d9,

Rerun:

“I'm very concerned that European citizens will have lack of access or much lower access to some of the new medicines” says CEO of Novo Nordisk. He also share some interesting perspectives about the importance of purpose and their new weight loss drug.

The production team on this episode were PLAN-B’s Niklas Figenschau Johansen and Nikolai Ovenberg. Background research was done by Sigurd Brekke with input from portfolio manager Gemma Game.

Watch the episode on YouTube: Norges Bank Investment Management - YouTube
Want to learn more about the fund? The fund | Norges Bank Investment Management (nbim.no)
Follow Nicolai Tangen on LinkedIn: Nicolai Tangen | LinkedIn
Follow NBIM on LinkedIn: Norges Bank Investment Management: Administrator for bedriftsside | LinkedIn
Follow NBIM on Instagram: Explore Norges Bank Investment Management on Instagram

‌

Episode description

Rerun: Lars Fruergaard Jørgensen CEO of Novo Nordisk

Episode description